Your browser is no longer supported. Please, upgrade your browser.
BioCryst Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.28 Insider Own1.30% Shs Outstand179.11M Perf Week33.91%
Market Cap2.91B Forward P/E- EPS next Y-0.95 Insider Trans-13.21% Shs Float177.94M Perf Month30.41%
Income-226.80M PEG- EPS next Q-0.30 Inst Own59.20% Short Float14.66% Perf Quarter2.31%
Sales114.00M P/S25.49 EPS this Y-16.00% Inst Trans1.38% Short Ratio7.43 Perf Half Y0.52%
Book/sh-0.82 P/B- EPS next Y18.00% ROA-78.10% Target Price20.33 Perf Year75.91%
Cash/sh1.06 P/C14.56 EPS next 5Y17.10% ROE261.10% 52W Range8.37 - 18.48 Perf YTD11.77%
Dividend- P/FCF- EPS past 5Y-13.10% ROI-69.30% 52W High-16.23% Beta2.42
Dividend %- Quick Ratio1.80 Sales past 5Y-18.10% Gross Margin93.90% 52W Low84.95% ATR1.07
Employees246 Current Ratio1.90 Sales Q/Q572.10% Oper. Margin- RSI (14)60.28 Volatility12.90% 7.10%
OptionableYes Debt/Eq- EPS Q/Q-25.70% Profit Margin- Rel Volume1.67 Prev Close15.48
ShortableYes LT Debt/Eq- EarningsNov 03 BMO Payout- Avg Volume3.51M Price15.48
Recom2.10 SMA2010.48% SMA5020.72% SMA2008.77% Volume0 Change0.00%
Dec-10-21Initiated Oppenheimer Outperform $16
Aug-06-21Downgrade Jefferies Buy → Hold
Aug-03-21Initiated Cantor Fitzgerald Overweight $21
Mar-01-21Initiated Cowen Outperform $16
Sep-29-20Resumed JP Morgan Overweight $7
Jun-17-20Initiated BTIG Research Neutral
May-05-20Upgrade Barclays Equal Weight → Overweight $7
Nov-15-19Upgrade BofA/Merrill Neutral → Buy $5 → $4
May-24-19Downgrade RBC Capital Mkts Outperform → Sector Perform $16 → $4.50
Nov-16-18Resumed Piper Jaffray Overweight $15
Aug-08-18Resumed JP Morgan Overweight $9
Jul-17-18Upgrade BofA/Merrill Underperform → Neutral
Jun-22-18Initiated Seaport Global Securities Neutral
Jan-02-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Dec-20-17Initiated Barclays Equal Weight $6
Sep-15-17Initiated RBC Capital Mkts Sector Perform $6
Sep-06-17Upgrade JP Morgan Neutral → Overweight
Sep-06-17Upgrade Jefferies Hold → Buy
Feb-16-17Initiated Ladenburg Thalmann Buy $11
Aug-12-16Upgrade Piper Jaffray Neutral → Overweight
Jan-14-22 04:31AM  
Jan-13-22 04:20PM  
Jan-11-22 01:48PM  
Jan-10-22 01:37PM  
Jan-07-22 09:25AM  
Jan-04-22 04:15PM  
Dec-15-21 08:45AM  
Dec-08-21 06:38PM  
Dec-07-21 04:38PM  
Dec-03-21 07:00AM  
Nov-30-21 11:18AM  
Nov-29-21 10:00AM  
Nov-23-21 07:21AM  
Nov-22-21 07:10AM  
Nov-12-21 07:00AM  
Nov-05-21 07:00AM  
Nov-03-21 02:31PM  
Nov-02-21 07:00AM  
Nov-01-21 07:00AM  
Oct-27-21 03:04PM  
Oct-26-21 07:00AM  
Oct-25-21 05:23PM  
Oct-20-21 07:00AM  
Oct-13-21 10:00AM  
Oct-04-21 07:00AM  
Sep-30-21 06:17AM  
Sep-21-21 07:00AM  
Sep-20-21 07:00AM  
Sep-16-21 11:50AM  
Sep-15-21 08:20PM  
Sep-09-21 07:00AM  
Sep-03-21 07:00AM  
Sep-02-21 04:01PM  
Sep-01-21 01:45PM  
Aug-26-21 07:00AM  
Aug-25-21 04:01PM  
Aug-23-21 06:47AM  
Aug-10-21 06:55PM  
Aug-09-21 04:01PM  
Aug-06-21 02:31AM  
Aug-05-21 04:08PM  
Aug-03-21 07:00AM  
Jul-28-21 07:00AM  
Jul-22-21 07:00AM  
Jul-19-21 06:05PM  
Jul-16-21 06:26AM  
Jul-15-21 09:41AM  
Jul-12-21 07:04AM  
Jul-10-21 10:00AM  
Jul-01-21 04:15PM  
Jun-29-21 07:31AM  
Jun-16-21 07:00AM  
Jun-07-21 01:47AM  
Jun-03-21 07:00AM  
May-26-21 07:00AM  
May-21-21 06:27AM  
May-18-21 09:00AM  
May-17-21 01:10PM  
May-12-21 09:25AM  
May-07-21 02:01AM  
May-06-21 09:31PM  
May-05-21 07:00AM  
Apr-30-21 09:22AM  
Apr-29-21 05:03PM  
Apr-22-21 07:00AM  
Apr-20-21 09:30AM  
Apr-14-21 03:42PM  
Apr-08-21 01:19AM  
Apr-07-21 07:00AM  
Mar-24-21 12:16PM  
Mar-22-21 01:27PM  
Mar-19-21 07:00AM  
Mar-15-21 07:00AM  
Mar-11-21 08:30AM  
Mar-02-21 07:00AM  
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase I clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. BioCryst Pharmaceuticals, Inc. has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. The company was founded in 1986 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stonehouse Jon PPresident & CEOJan 11Option Exercise4.73184,000870,3201,085,602Jan 13 04:45 PM
Stonehouse Jon PPresident & CEOJan 11Sale15.04184,0002,767,360901,602Jan 13 04:45 PM
Babu Yarlagadda SChief Discovery OfficerDec 07Option Exercise4.7362,000293,260245,156Dec 09 04:38 PM
Babu Yarlagadda SChief Discovery OfficerDec 07Sale12.2030,100367,220215,056Dec 09 04:38 PM
MILANO VINCENTDirectorNov 24Buy12.197,50091,42517,500Nov 24 06:35 PM
Doyle AnthonyChief Financial OfficerNov 23Buy12.4835,258440,02093,719Nov 24 06:35 PM
ABERCROMBIE GEORGE BDirectorNov 15Option Exercise3.325,00016,6005,000Nov 17 04:27 PM
ABERCROMBIE GEORGE BDirectorNov 15Sale12.275,00061,3500Nov 17 04:27 PM
Hutson Nancy JDirectorOct 15Option Exercise3.46105,000363,450170,073Oct 19 04:21 PM
Hutson Nancy JDirectorOct 15Sale15.40105,0001,617,00065,073Oct 19 04:21 PM
ABERCROMBIE GEORGE BDirectorSep 15Option Exercise2.635,00013,1505,000Sep 17 04:31 PM
ABERCROMBIE GEORGE BDirectorSep 15Sale15.065,00075,3000Sep 17 04:31 PM
LEE KENNETH B JRDirectorSep 13Option Exercise3.2215,00048,30030,252Sep 15 04:26 PM
LEE KENNETH B JRDirectorSep 13Sale15.356,00092,10024,252Sep 15 04:26 PM
ABERCROMBIE GEORGE BDirectorSep 10Option Exercise2.8671,000202,71074,000Sep 14 04:14 PM
ABERCROMBIE GEORGE BDirectorSep 10Sale15.0974,0001,116,6600Sep 14 04:14 PM
ABERCROMBIE GEORGE BDirectorJul 15Option Exercise2.635,00013,1508,000Jul 19 04:39 PM
ABERCROMBIE GEORGE BDirectorJul 15Sale15.695,00078,4503,000Jul 19 04:39 PM
Hutson Nancy JDirectorJun 10Option Exercise3.1523,33373,54988,406Jun 14 04:29 PM
Hutson Nancy JDirectorJun 10Sale16.8623,333393,39465,073Jun 14 04:29 PM
Sheridan William PChief Medical OfficerMay 28Option Exercise5.3891,814493,826106,289Jun 01 04:33 PM
Sheridan William PChief Medical OfficerMay 28Sale15.0291,8141,379,04614,475Jun 01 04:33 PM
Sheridan William PChief Medical OfficerMay 27Option Exercise5.2771,759378,11486,234Jun 01 04:33 PM
Sheridan William PChief Medical OfficerMay 27Sale15.0071,7591,076,38514,475Jun 01 04:33 PM
ABERCROMBIE GEORGE BDirectorMay 24Option Exercise2.636,66717,5349,667May 26 04:12 PM
ABERCROMBIE GEORGE BDirectorMay 24Sale13.906,66792,6713,000May 26 04:12 PM
Barnes Alane PChief Legal OfficerMay 12Option Exercise4.7335,852169,580146,127May 13 04:43 PM
Barnes Alane PChief Legal OfficerMay 11Option Exercise4.14102,780425,442213,055May 13 04:43 PM
Barnes Alane PChief Legal OfficerMay 11Sale12.04102,7801,237,471110,275May 13 04:43 PM
ABERCROMBIE GEORGE BDirectorMay 10Sale12.707,00088,9003,000May 12 05:02 PM
Jones Michael LExec. Director, Finance - PAOMar 18Option Exercise3.514,50015,7955,348Mar 22 04:19 PM
Sheridan William PSenior VP - CMOFeb 22Option Exercise4.1541,250171,18852,725Feb 24 04:34 PM
Sheridan William PSenior VP - CMOFeb 22Sale11.5741,250477,26211,475Feb 24 04:34 PM
Babu Yarlagadda SSenior VP - Drug DiscoveryFeb 19Option Exercise4.1550,000207,500205,587Feb 23 04:25 PM